DEFA14A: STAAR Surgical Merger Price Boosted to $30.75/Share

STAAR Surgical Company announced an amendment to its merger agreement with Alcon, increasing the cash consideration for shareholders to $30.75 per share.

Summary

• STAAR Surgical Company entered into Amendment No. 2 to its Agreement and Plan of Merger with Alcon Research, LLC and Rascasse Merger Sub, Inc. on December 9, 2025.
• The cash consideration to be paid to holders of STAAR common stock, if the merger is consummated, has been increased to $30.75 per share from the previous $28.00 per share.
• Restricted stock unit (RSU) awards granted prior to August 4, 2025, or held by a director, and performance-based restricted stock unit (PSU) awards will be converted into Alcon Inc. restricted stock unit awards.
• Company PSU awards will be deemed earned at 100% of target performance for conversion purposes.
• Director RSU awards will become fully vested at the closing of the Merger.
• The amendment eliminates any 280G gross-ups and related tax indemnification arrangements to be entered into by the Company in connection with the Merger.

Sentiment

Score: 8

Explanation: The significant increase in the cash merger consideration for shareholders, coupled with favorable terms for equity award holders, indicates a strong positive sentiment regarding the transaction for STAAR Surgical's investors.

Positives

• Increased cash consideration for shareholders from $28.00 to $30.75 per share, representing a $2.75 per share increase.
• Performance-based restricted stock unit awards (PSUs) will be deemed earned at 100% of target, which is a favorable outcome for award holders.
• Director restricted stock unit awards will become fully vested at the closing of the merger.

Negatives

• Elimination of 280G gross-ups and related tax indemnification arrangements, which could negatively impact certain executives.

Risks

• Potential for events, changes, or circumstances that could terminate the merger agreement or delay/prevent consummation.
• Failure to obtain approval of the proposed transaction from STAAR Surgical Company's stockholders.
• Failure to obtain required regulatory approvals or satisfy other closing conditions within expected timeframes or at all.
• Disruption of management's attention from ongoing business operations due to the proposed transaction.
• Impact of the announcement on the Company's ability to retain and hire key personnel and maintain relationships with customers, suppliers, and other business partners.
• Inability of the Company to meet expectations regarding the timing and completion of the transaction.
• Outcome of any legal proceedings that may be instituted against the Company related to the proposed transaction.
• Significant decline in the Company's stock price if the proposed transaction is not consummated.

Future Outlook

The future outlook is centered on the successful consummation of the merger with Alcon, subject to stockholder approval and regulatory clearances. The company anticipates the transaction will proceed as amended, leading to STAAR Surgical becoming a wholly-owned subsidiary of Alcon.

Management Comments

• STAAR Surgical Company, through its CEO Stephen C. Farrell, executed Amendment No. 2 to the Agreement and Plan of Merger, signifying agreement to the revised terms including the increased per-share consideration.
• Alcon Research, LLC and Rascasse Merger Sub, Inc., through their CEO David Endicott, executed Amendment No. 2, indicating their commitment to the revised merger terms.

Industry Context

This amendment reflects ongoing consolidation within the ophthalmology and medical device sectors, where larger players like Alcon seek to acquire specialized innovators such as STAAR Surgical. The increased offer price suggests competitive dynamics or a re-evaluation of STAAR's intrinsic value within the market, potentially setting a benchmark for similar acquisitions in the sector.

Corporate Governance

Legal Proceedings

• Risk of legal proceedings being instituted against the Company related to the proposed transaction.

Stakeholder Impact

• **Shareholders:** Directly benefit from the increased cash consideration of $30.75 per share, representing a higher premium for their investment.
• **Equity Award Holders (Employees/Directors):** Benefit from the conversion of RSUs and PSUs into Alcon awards, with PSUs deemed earned at 100% of target and director RSUs vesting at closing, providing certainty and value realization.
• **Executives:** Those who might have been eligible for 280G gross-ups will no longer receive them, potentially impacting their net compensation related to change-in-control payments.
• **Employees (General):** Face potential disruption and uncertainty related to management's attention being diverted by the merger and the ability of the Company to retain key personnel post-acquisition.

Next Steps

• Obtain approval of the proposed transaction from STAAR Surgical Company's stockholders.
• Obtain certain required regulatory approvals.
• Satisfy other closing conditions to the completion of the proposed transaction.
• Consummation of the merger, resulting in STAAR Surgical becoming a wholly-owned subsidiary of Alcon.

Key Dates

Recommendation

For existing shareholders, holding the stock until the merger's consummation is advisable to receive the increased cash consideration of $30.75 per share. The increased offer provides a clear exit price, and the primary remaining steps are regulatory and shareholder approvals. For new investors, the arbitrage opportunity might be limited depending on the current market price relative to the new offer, making a 'hold' for existing shareholders the most prudent recommendation.

Keywords

STAAR Surgical, Alcon, Merger Agreement, Acquisition, Cash Offer, Shareholder Value, Restricted Stock Units, Performance Stock Units, Corporate Governance, SEC Filing, DEFA14A, 8-K